Immunoassay Market Analysis - Leading players and Business Intelligence
According to the new market research report Immunoassay Market is expected to reach USD 27.15 Billion by 2023 from USD 20.19 Billion in 2018, at a CAGR of 6.1%.
The
increasing incidence of chronic and infectious diseases, technological
advancements in immunoassay instruments and introduction of novel
automated systems, and growth in the biotechnology and biopharmaceutical
industries are some the major factors driving the growth of this
market.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=436
- By platform, this market is classified into CLIAs, radioimmunoassays (RIAs), colorimetric immunoassays (CIs), fluorescence immunoassays (FIAs), and other platforms.
- On the basis product and service, this market is classified into reagents and kits, analyzers, and software and services. In 2017, the reagents and kits segment accounted for the largest share of the immunoassays market.
- On the basis
of technology, the immunoassay market is segmented into ELISA, rapid
tests, western blotting, enzyme-linked immunospot (ELISPOT), immuno-PCR,
and other immunoassay technologies.
The immunoassays
market is consolidated in nature due to the presence of a large number
of players. Key players in the market include Abbott Laboratories (US),
Roche (Switzerland), Siemens (Germany), Danaher Corporation (US),
DiaSorin (Italy), Ortho Clinical Diagnostics (US), Thermo Fisher
Scientific (US), QIAGEN (Netherlands), Becton, Dickinson and Company
(US), Bio-Rad Laboratories (US), Merck (Germany), Agilent Technologies
(US), Quidel Corporation (US), PerkinElmer (US), Mindray (China), and
Bio-Techne Corporation (US).
The key strategies followed by most
companies in the immunoassay market are product launches and
partnerships, collaborations, & agreements. These strategies
accounted for the largest share of the overall growth strategies mapped
from 2015 to 2018 (till March). Some of the leading players who adopted
these strategies include Roche (Switzerland), Abbott Laboratories (US),
Danaher Corporation (US), bioMérieux (France), and Sysmex Corporation
(Japan).
In 2017, Roche was the leading player in the
immunoassays market. This position of the company can be attributed to
its wide product portfolio, which includes clinical chemistry and
immunochemistry solutions, molecular diagnostic products, tissue
diagnostic instruments, reagents, and kits. Under its flagship brand,
Cobas, the company offers a variety of IVD instruments, reagents, and
kits that are widely used by end users across the globe.
Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=436
Abbott
Laboratories accounted for the second-largest share of the immunoassay
market in 2017. With the acquisition of Alere, Inc. (US) in 2017, the
company was able to enhance its presence in the immunoassays market.
With the completion of this acquisition, Abbott strengthened its
diagnostics portfolio and established itself as a leading player in the
point-of-care testing and immunoassay market.
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Comments
Post a Comment